News

Nov 14, 2019

A recent analysis of more than 29,000 adults listed on the national heart transplant registry from 2006 to 2015 suggests that there are large discrepancies in how sick patients are when they receive heart transplants. Even though there are rules to determine who gets a transplant, the patients who received a heart transplant, the overall survival rate after transplant was similar across all centers: about 77%. However   the low survival benefit hospitals are playing it safe, giving organs to less critical patients who receive a smaller benefit from the transplant.

Nov 13, 2019

Three common  justifications for the persistent discrimination and gender bias have been debunked by Drexel University College of Medicine researchers. The article written by the researchers states that gender equity can be fostered by employing the same basic scientific principles which are utilised for solving problems with scientific medicine. 

Nov 13, 2019

A new research has shown how exactly the e-cigarettes in cases of young people cause damage to the brain, heart, blood vessels and lungs. The study was published in the European Heart Journal and has been successful in identifying the mechanisms which were unclear until now. The researchers added that this calls for the need to focus on the governing policies and ban their use. 

Journal Abstracts

Nov 13, 2019

Prof Johann Christian Virchow, MD et al conducted two parallel-group, double-blind, randomized, active-controlled, phase 3 trials—Triple in Asthma With Uncontrolled Patients on Medium Strength of ICS + LABA (TRIMARAN) and Triple in Asthma High Strength Vs ICS/LABA HS and Tiotropium (TRIGGER)—involving individuals from over 200 sites across more than 16 countries to compare the efficacy of a single-inhaler triple therapy in asthma. Enrolled patients were initially treated with BDP/FF for 2 weeks, then randomized to treatment using an interactive response technology system with a balanced block randomization scheme stratified by country. In TRIMARAN, patients were randomized to 52 weeks of BDP/FF/G or BDP/FF, two inhalations twice daily. Among patients who received ≥ 1 dose of study treatment, safety was evaluated. Overall, among those with uncontrolled asthma, adding a long-acting muscarinic antagonist to inhaled corticosteroid plus long-acting β2-agonist therapy enhanced lung function and decreased aggravations.

 

Nov 13, 2019

In 87 neonatal and ophthalmic centers in 26 countries of 225 infants with birth weight less than 1,500 g who met criteria for treatment for retinopathy, Prof Andreas Stahl, MD et al assessed the efficiency and safety of intravitreal ranibizumab vs laser therapy in treatment of retinopathy of prematurity (ROP). Individuals were randomized evenly (1:1:1) to receive a single bilateral intravitreal dose of ranibizumab 0·2 mg or ranibizumab 0·1 mg, or laser therapy. In the treatment of ROP, compared with laser therapy and with an acceptable 24-week safety profile, it was discovered that ranibizumab 0·2 mg could be better than laser therapy, with less hostile ocular outcomes.

Nov 13, 2019

Given that a prolonged progression-free survival was achieved with maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, in patients with platinum-sensitive, recurrent ovarian cancer, who had a response to their last platinum-based chemotherapy, examined in the ENGOT-OV16/NOVA trial, Josep M. del Campo, MD et al evaluated the clinical benefit as well as patient-reported outcomes in those who had a partial response (PR) and complete response (CR) to their last platinum-based treatment. Enrolled patients were 553 in total. A germline BRCA mutation (gBRCAmut) was present in 203 patients, of these, a PR and a CR to their last platinum-based therapy was reported in 99 and 104, respectively; of 350 patients without a proved gBRCAmut (non–gBRCAmut), a PR and a CR was achieved in 173 and in 177, respectively. In both the gBRCAmut cohort and the non–gBRCAmut cohort, improved progression-free survival was observed in relation to treatment with niraparib vs placebo. Overall, maintenance therapy with niraparib provided clinical benefit to patients irrespective of response to the last platinum-based therapy.

Recent Articles

Nov 14, 2019

This course, directed by Roy Sanders, MD is going to be held at Tampa, Florida during November 15-17, 2019. It is designed to provide the orthopedic surgeon with a comprehensive update on the evolving concepts and techniques in orthopedic trauma. The distinguished faculty will share their knowledge and expertise on a wide variety of relevant topics related to both upper and lower extremity trauma.

Nov 14, 2019

David W. Lam presented a talk on the current updates in the field of Diabetes Technology with the help of cases. The speaker has emphasized how the new treatment modalities are helpful in improving the state of Diabetes care. The speaker further explained that newer updates have also improved outcomes in Diabetes Management. 

Nov 14, 2019

The 5th International Conference and Exhibition on Lung & Respiratory Care to be held during November 23-24, 2020 in Dubai, UAE. The upcoming conference will be organized around the theme “Revolutions in Lungs & Respiratory Diseases". This conference can provide principles to a different strategy for acquainting recent data on metabolism with members with the target that the arrangement of the results will provide a groundwork workplace yield and additionally a vital instrument to be shared among patients and clinicians.

Clinical Research

Nov 14, 2019

This is a single institution, single-arm, window of opportunity pilot trial of pembrolizumab in patients with resectable malignant pleural mesothelioma. All patients will undergo a pretreatment PET/CT scan for clinical staging and a VATS procedure to acquire pretreatment tissue. Three cycles of pembrolizumab will then be administered (200 mg IV every 21 days). A PET/CT scan will then be repeated to assess response to pembrolizumab and then surgical resection will be performed via an extended/pleurectomy decortication at least 4 weeks after the third dose of pembrolizumab. Standard adjuvant chemotherapy consisting of cisplatin and pemetrexed for 4 cycles (every 21 days) will be given starting about 6-8 weeks following surgery after a new baseline CT scan is obtained. Restaging CT scans will be obtained to assess response after every two cycles of chemotherapy. After the completion of standard chemotherapy, optional adjuvant treatment with pembrolizumab will be given to eligible patients for 1-year post-surgery.

Nov 14, 2019

This study aims to determine if intermittent dosing is deliverable, based on patient and professional willing to take part in a randomized trial evaluating less rather than the standard duration of treatment. The trial will evaluate treatment compliance, Progression-Free Survival, and Quality of Life, to inform whether a subsequent definitive trial is justified and how it should be designed.

Nov 14, 2019

The goal of this prospective randomized double-blinded placebo-controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. Participants will be randomized to one of three groups after administration of general anesthesia; one dose of .5 mg/kg intravenous (IV) Ketamine, 1.0 mg/kg of IV Ketamine, or IV placebo. Ketamine's effect on postoperative pain and opioid use will be measured as well. Electroencephalogram (EEG) will be utilized during the surgical procedure to evaluate its potential as a possible predictive device for delirium.

Nov 14, 2019

The goal of this prospective randomized double-blinded placebo-controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. Participants will be randomized to one of three groups after administration of general anesthesia; one dose of .5 mg/kg intravenous (IV) Ketamine, 1.0 mg/kg of IV Ketamine, or IV placebo. Ketamine's effect on postoperative pain and opioid use will be measured as well. Electroencephalogram (EEG) will be utilized during the surgical procedure to evaluate its potential as a possible predictive device for delirium.

Nov 14, 2019

This study involves 3 phases that modify current Interactive Preventative Health Record-Colorectal Cancer Screening (IPHR-CRCS) modules to address each patient's individual colorectal cancer screening (CRCS) knowledge, attitudes, preferences, and test-specific barriers. The study will engage patients, ages 50-75 years who are non-adherent to CRCS, to assess their CRCS test preferences and corresponding test-specific barriers in "real-time". Based on patient characteristics (e.g. age, personal and family history, physician CRCS recommendation, CRCS test preferences, top test-specific barriers), tailored messages/videos will appear in the pop-up screens to address/reduce the top patient-reported, test-specific CRCS barriers while incorporating an action plan for CRCS adherence. The investigators hypothesize that modifying the IPHR-CRCS module to address each patient's individual CRCS knowledge, attitudes, preferences, and test-specific barriers will further increase CRCS.

Nov 12, 2019

Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.

Nov 12, 2019

 

This is a single patient investigative treatment study. The patient was diagnosed with a retinal tumor in one eye. In the last 2 years, the patient has been treated with all available and conventional therapies, including intraocular injections of Avastin and Lucentis, steroids, and photodynamic therapy. Any positive results were short-term, and caused an eventual decline in central vision. Aflibercept has been shown to be effective against the growth of new vessels, secondary to macular degeneration. This study proposes that it may also be more effective in treating this particular patient and case. The study treatment plan is for 6 months initially, with the intention to continue treatment.

Publications

Nov 14, 2019

Essentials of Dental Assisting and Boyd: Dental Instruments, 7e, 6th Edition is a Text, Workbook, and is authored by Debbie S. Robinson & Doni L. Bird & Linda Bartolomucci Boyd. It will be available in March 2020.

Nov 13, 2019

World Journal of Pediatric and Congenital Heart Surgery is a bimonthly, peer-reviewed scientific publication dedicated to the advancement and dissemination of knowledge pertaining to congenital heart anomalies, and pediatric heart diseases in general. It focuses on the surgical aspect of the care of infants, children, and adults. 

Nov 13, 2019

European Journal of Cardio-Thoracic Surgery provides a medium for the publication of high-quality original scientific reports documenting progress in cardiac and thoracic surgery. The journal publishes reports of significant clinical and experimental advances related to surgery of the heart, the great vessels and the chest. 

Nov 13, 2019

Reviews in Endocrine and Metabolic Disorders  is an international journal dedicated to students, clinicians and researchers involved in the broad area of endocrinology and metabolism. The mission of this review journal is to keep those interested individuals informed of all the latest exciting advancements that are essential to their research or clinical practice.

Nov 13, 2019

Endoscopy is the premier journal for information on the latest technologies and international developments in gastrointestinal endoscopy. Under the expert direction of an international editorial board, this journal presents high-quality content that addresses the needs of endoscopists, surgeons, clinicians, and researchers across the globe.

Nov 13, 2019

Diagnostic and Interventional Radiology (Diagn Interv Radiol) is the open access, online-only official publication of Turkish Society of Radiology. It is published bimonthly and the journal’s publication language is English. The journal is a medium for original articles, reviews, pictorial essays, technical notes and case reports related to all fields of diagnostic and interventional radiology.

Nov 10, 2019

The first edition of Clinical Periodontology for the Dental Hygienist, published by Elsevier and authored by Michael G. Newman, Gwen Essex, Lory Laughter, and Satheesh Elangovan will be releasing in June 2020.

Videos

Nov 14, 2019

Dr. Katja Kovacic presented a talk on functional nausea with an objective on understanding the classification and diagnostic challenges of functional GI disorders, identifying clues to the underlying pathology that co-morbidities may provide, understanding the limitations of diagnostic testing for upper GI motor disorders. 

Nov 14, 2019

Dr. Katja Kovacic presented a talk on functional nausea with an objective on understanding the classification and diagnostic challenges of functional GI disorders, identifying clues to the underlying pathology that co-morbidities may provide, understanding the limitations of diagnostic testing for upper GI motor disorders. 

Nov 14, 2019

In this fast-paced case review, vRad Chief Medical Officer, Dr. Benjamin W. Strong, utilizes cinematic and still imagery to explore the findings and diagnosis of some of his favorite cases complied from vRad’s extensive teaching library. The diagnoses covered include Foreign body, Globe rupture, Lens displacement, Retinal detachment, Retinal hemorrhage, Optic nerve avulsion, Blowout fracture, Carotid-cavernous fistula etc. 

Nov 14, 2019

In this fast-paced case review, vRad Chief Medical Officer, Dr. Benjamin W. Strong, utilizes cinematic and still imagery to explore the findings and diagnosis of some of his favorite cases complied from vRad’s extensive teaching library. The diagnoses covered include Foreign body, Globe rupture, Lens displacement, Retinal detachment, Retinal hemorrhage, Optic nerve avulsion, Blowout fracture, Carotid-cavernous fistula etc. 

Case Studies

Nov 12, 2019

This is a case of a 51-year-old man with relapsed lambda light chain MM who developed abrupt asymptomatic skin metastases. Biopsy revealed a dermis replete of atypical plasma cells, positive for CD138 and CD45. In situ hybridization confirmed lambda light chain restriction. Despite rescue antimyeloma therapy with the anti-CD38 drug daratumumab, he rapidly declined clinically and succumbed to the disease four weeks after presentation. 

Nov 11, 2019

Ectodermal dysplasia is a rare genetic disorder that affects ectodermally derived structures, including teeth, nails, hair, and sweat glands. Hypohidrotic ectodermal dysplasia is the most common type, with oligodontia being the most striking dental feature. Prosthetic rehabilitation in children with ectodermal dysplasia is an important step toward improving their overall quality of life. The fixed prosthesis has the advantages of being more stable in the mouth with good child compliance and a good aesthetic outcome. The patient was a 5-year-old Middle Eastern boy with oligodontia caused by ectodermal dysplasia. He was managed by fabrication of an upper functional space maintainer and a lower fixed partial denture to restore occlusion, masticatory function, aesthetics, and overall quality of life.

Nov 11, 2019

The patient presented with hemoptysis and was diagnosed with stage IIIA poorly differentiated NSCLC via bronchoscopic biopsy. The initial treatment plan was surgery after neoadjuvant chemotherapy. Despite conventional chemotherapy, follow-up chest CT showed gradual tumor progression and she decided against further treatment after fifth-line chemotherapy. However, the size of lung mass was markedly decreased on follow-up chest CT one year after ceasing chemotherapy. Also, follow-up PET images showed decreased metabolic activity in the lung mass and a percutaneous biopsy specimen from the diminished lung mass revealed no viable tumor cells. A diagnosis of spontaneous remission (SR) of NSCLC was confirmed, and the patient was without tumor progression on follow-up nine months later.

Nov 11, 2019

Posterior reversible encephalopathy syndrome (PRES) is a clinical syndrome of headache, altered mental status, and seizures with reversible mainly posterior leukoencephalopathy on neuroimaging. Precipitating factors for PRES are multifactorial and include autoregulatory failure due to changes in blood pressure, metabolic derangements, and cytotoxic medications. Taha Nisar et al report the second case of cyclophosphamide-induced PRES in a patient with anti-glomerular basement membrane (Anti-GBM) positive vasculitis. In the acute setting, PRES can be challenging to distinguish from cerebral venous sinus thrombosis or cerebral vasculitis based on clinical presentation. Neuroimaging with magnetic resonance imaging (MRI) of the brain along with a vessel imaging, can help reach the diagnosis